JERUSALEM, March 29, 2016 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQ:
ORMP) (http://www.oramed.com), a developer of oral drug delivery
systems, announced today that the Company's patent for its
invention, titled "Methods and Compositions for Oral
Administrations of Proteins" has been granted by the Indian Patent
Office.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of
oral delivery solutions for drugs currently delivered via
injection. Established in 2006, Oramed's Protein Oral Delivery
(PODTM) technology is based on over 30 years of research
by top scientists at Jerusalem's
Hadassah Medical Center. Oramed is seeking to revolutionize the
treatment of diabetes through its proprietary flagship product, an
orally ingestible insulin capsule (ORMD-0801). Having completed
multiple Phase IIa trials, the Company's Phase IIb trial on type 2
diabetes is ongoing under an Investigational New Drug application
with the U.S. Food and Drug Administration. In addition Oramed is
developing an oral GLP-1 analog capsule (ORMD-0901).
For more information, the content of which is not part of
this press release, please visit
http://www.oramed.com
Forward-looking statements: This press release contains
forward-looking statements. For example, we are using
forward-looking statements when we discuss that ORMD-0801 has the
potential to create a new paradigm in the treatment of diabetes,
potentially slowing disease progression and delaying or even
eliminating late-stage complications, that orally administered
insulin should bring with it enhanced patient compliance or when we
discuss our clinical trials and revolutionizing the treatment of
diabetes with our products. These forward-looking statements
are based on the current expectations of the management of Oramed
only, and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those
described in the forward-looking statements, including the risks
and uncertainties related to the progress, timing, cost, and
results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent
protection for our product candidates; competition from other
pharmaceutical or biotechnology companies; and our ability to
obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements; delays
or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our
technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the SEC.
Company Contact
Oramed Pharmaceuticals
Ariella Vaystooch
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: ariella@oramed.com
SOURCE Oramed Pharmaceuticals Inc.